Pharma: Other News To Note

• Boehringer Ingelheim GmbH, of Ingelheim, Germany, expanded biopharmaceutical development and manufacturing capabilities at its cell culture and microbial sites in Biberach, Germany, and Vienna, Austria. The moves are designed to enhance cell line development with the company's Bi-Hex high-expression system and microbial strain and to expand process development services for contract manufacturing. Boehringer Ingelheim said it invested about €17 million (US$22.7 million) in the expansion, which includes current good manufacturing practice cell banking, process science, cell line development and quality laboratories.